Physician profile
Berly Sojan
NPI 1609413152
$3,065.35
in general payments reported to CMS, 2019-2025
27 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.06 · 2022: $135 · 2024: $1,072 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $563.92 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $398.44 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $328.84 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $271.73 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $180.34 | 2024-2025 | |
| Pfizer INC. | $161.00 | 2024-2025 | |
| Shield Therapeutics INC | $141.47 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.07 | 2024-2025 | |
| Glaxosmithkline, LLC. | $118.34 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $104.08 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.61 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $72.02 | 2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $57.67 | 2024 | Rexulti |
| Boston Scientific Corporation | $57.16 | 2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Merck Sharp & Dohme LLC | $53.65 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.59 | 2025 | Nexletol |
| Exact Sciences Corporation | $45.72 | 2024-2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $41.85 | 2024-2025 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $37.52 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $35.08 | 2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.19 | 2024-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $24.42 | 2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.38 | 2024 | Abilify Maintena |
| Inspire Medical Systems, INC. | $19.94 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $18.39 | 2022 | |
| Astellas Pharma US INC | $18.33 | 2024 | Veozah |
| Dexcom, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berly Sojan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.